Healthcare Industry News: Merck
News Release - March 21, 2018
Juniper Pharmaceuticals Appoints Richard Messina to Board of DirectorsBOSTON, March 21, 2018 -- (Healthcare Sales & Marketing Network) -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP), a diversified healthcare company with core businesses of its CRINONE® (progesterone gel) franchise and fee-for-service pharmaceutical development and manufacturing business JPS, today announced the appointment of Richard Messina to the Company's Board of Directors.
"We welcome Richard to Juniper's Board of Directors. As a long-term shareholder, Richard's perspective will be a valuable contribution to our ongoing process of reviewing strategic alternatives while we continue to drive growth in our core businesses," said Alicia Secor, Juniper's President and CEO. "Richard has witnessed Juniper transform throughout the years, and we look forward to working with him as we seek to build shareholder value."
Mr. Messina is the Founder, President and Chief Executive Officer of The Benchmark Company, LLC, an investment banking and financial advisory firm.
About Juniper Pharmaceuticals
Juniper Pharmaceuticals, Inc.'s core businesses include its CRINONE® (progesterone gel) franchise and Juniper Pharma Services, which provides high-end fee-for-service pharmaceutical development and clinical trials manufacturing to clients. The Company is also leveraging its differentiated intravaginal ring technology, which offers the potential to address unmet needs in women's health. Please visit www.juniperpharma.com for more information.
Juniper Pharmaceuticals™ is a trademark of Juniper Pharmaceuticals, Inc., in the U.S. and EU.
CRINONE® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan plc in the U.S.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Juniper's exploration of strategic alternatives. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include, but are not limited to the uncertainty associated with being able to identify, evaluate and complete any strategic alternative, the impact of the announcement of the Company's review of strategic alternatives, as well as any strategic alternative that may be pursued, on the Company's business. For a discussion of certain risks and uncertainties associated with Juniper Pharmaceuticals' forward-looking statements, please review the Company's reports filed with the SEC, including, but not limited to, its Annual Report on Form 10-K for the period ended December 31, 2017 and subsequent filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. These statements are based on management's current expectations and Juniper Pharmaceuticals does not undertake any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law.
Source: Juniper Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.